Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
Participants are randomized in a ratio of 1:1:1 into 20 µg recombinant hepatitis B vaccine group at months 0, 1, and 6 or 20µg recombinant hepatitis B vaccine group at months 0, 1, 2, and 6 or 60µg recombinant hepatitis B vaccine group at months 0, 1, 2, and 6. HBsAg and anti‐HBs will be tested during the study period. Adverse reactions will be recorded after vaccination.
Epistemonikos ID: 3b322d3fcdfcd549b4ff84db025b295e868cce21
First added on: Nov 24, 2021